西洛他唑与缺血性卒中

Cilostazol and ischemic stroke

西洛他唑通过抑制环核苷酸磷酸二酯酶-3提高细胞内环磷酸腺苷（cyclic adenosine monophosphate，cAMP）水平。其主要作用由cAMP所介导，包括抑制血小板聚集、抗血栓形成、血管扩张和抗内皮细胞增殖等。最近的实验研究表明，西洛他唑在干预急性脑缺血和慢性脑灌注不足方面显示出希望；临床试验亦证明其有效。文章总结了西洛他唑的药理学作用和机制，及其在缺血性卒中时的保护作用。

Cilostazol increases the level of intracellular cyclic adenosine monophosphate （cAMP） by inhibiting cyclic nucleotide phosphodiesterase-3. Its main role was induced by the increased cAMP, including the inhibition of platelet aggregation, anti-thrombosis, vasodilation, and anti-endothelial cell proliferation. Recent experimental studies have indicated that cilostazol is promising in the intervention of acute cerebral ischemia and chronic cerebral hypoperfusion. Clinical trials have also demonstrated its efficacy. This article summarizes the pharmacological effect and mechanism of cilostazol, as well as its protective effect during ischemic stroke.